Literature DB >> 12239063

Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferumoxides-enhanced MR imaging.

Kensaku Mori1, Juergen Scheidler, Thomas Helmberger, Nicolaus Holzknecht, Rolf Schauer, Carl Albrecht Schirren, Iris Bittmann, Martin Dugas, Maximilian Reiser.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the diagnostic accuracy of ferumoxides-enhanced MR imaging for screening malignant hepatic lesions before orthotopic liver transplantation.
MATERIALS AND METHODS: The study comprised 48 patients who underwent MR imaging within 6 months before transplantation. Imaging techniques included unenhanced and ferumoxides-enhanced T1-weighted gradient-echo and T2-weighted fast spin-echo sequences and ferumoxides-enhanced T2(*)-weighted gradient-echo sequences. Qualitative and quantitative analyses were performed; the gold standard was the histopathologic reports of explanted livers.
RESULTS: Twenty patients had malignant hepatic lesions, and 24 hepatocellular carcinomas were histopathologically proven. The mean area under the receiver operating characteristic curve and the mean sensitivity were significantly greater for the image sets with ferumoxides-enhanced gradient-echo sequences than for those without these sequences. The mean sensitivity and specificity of all sequences were 85% and 74% on a per-patient basis, respectively. The mean contrast-to-noise ratio was significantly greater for the ferumoxides-enhanced T2(*)-weighted gradient-echo sequences than for any other sequences and for the ferumoxides-enhanced T1-weighted gradient-echo sequences than for unenhanced sequences and the ferumoxides-enhanced T2-weighted fast spin-echo sequences.
CONCLUSION: Ferumoxides-enhanced gradient-echo sequences improved the diagnostic accuracy and the sensitivity for detecting malignant hepatic lesions in patients with end-stage cirrhosis of the liver. However, the specificity was not improved even after the administration of ferumoxides because of the false-positive lesions that were mainly the result of fibrotic changes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239063     DOI: 10.2214/ajr.179.4.1791045

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography.

Authors:  Riccardo Lencioni; Clotilde Della Pina; Jordi Bruix; Pietro Majno; Luigi Grazioli; Giovanni Morana; Antonella Filippone; Andrea Laghi; Carlo Bartolozzi
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 2.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

3.  Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT.

Authors:  R Golfieri; E Marini; A Bazzocchi; F Fusco; F Trevisani; C Sama; G Mazzella; S Cavuto; F Piscaglia; L Bolondi
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

4.  Health economic evaluation of ferucarbotran-enhanced MRI in the diagnosis of liver metastases in colorectal cancer patients.

Authors:  Lieven Annemans; Riccardo Lencioni; Hans Warie; Carlo Bartolozzi; Marco Ciceri; Ulrike Müller
Journal:  Int J Colorectal Dis       Date:  2007-10-02       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.